Navigation Links
JDRF to provide $1M in funding to SmartCells, Inc.
Date:10/22/2008

New York, NY and Beverly, MA [October 22, 2008] ~ The Juvenile Diabetes Research Foundation (JDRF) and SmartCells, Inc. today announced a partnership to advance SmartCells' SmartInsulin for the treatment of type 1 diabetes. SmartInsulin will be a once-a-day, glucose-regulated insulin that is administered by injection just under the skin. But unlike currently available insulins, SmartInsulin is designed to maintain continuous, tight control of blood glucose levels while reducing the risk of hypoglycemia like the pancreas does automatically in the absence of diabetes. As part of the agreement, JDRF will provide $1 million in first-year funding to support preclinical safety and efficacy testing. The partnership is structured to support milestone-based funding through proof-of-concept human clinical trials.

"JDRF's support will accelerate the commercial development of our SmartInsulin therapy for type 1 diabetes. Our formulation is designed to address the most critical issue in diabetes treatment achieving tight glucose control without inducing severe hypoglycemic episodes. To accomplish this, patients will only have to inject SmartInsulin once a day using the same needles currently used for conventional insulin. We expect these important treatment benefits will improve patient safety and quality of life while reducing diabetic complications," said Todd C. Zion, Ph.D., President and CEO of SmartCells. "We are very pleased to have JDRF's support for this program, and share their commitment to the development of breakthrough treatments for type 1 diabetes."

Aaron Kowalski, Ph.D., Director of JDRF's Metabolic Control Program, explained that JDRF is committed to supporting the development of unique therapies that can improve metabolic control for people with type 1 diabetes: "We believe that glucose-regulated insulin may represent a practical solution to the real needs of people with diabetes, and this collaboration illustrates our dedication to accelerating the pace of science leading to cures and treatments for people with type 1 diabetes by helping innovative companies test concepts and bring their products to patients faster."

Under the terms of the partnership, the $1 million grant will support testing the safety and efficacy of SmartInsulin in preclinical type 1 diabetes trials. The partnership is intended to accelerate the product's development and reduce the time needed to progress to human testing. The grant is part of JDRF's innovative Industry Discovery and Development Partnership Program, which supports companies developing drugs, treatments, and technologies to address type 1 diabetes and its complications.


'/>"/>

Contact: Leslie Schwartz
lschwartz@jdrf.org
212-479-7553
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide
2. Volcanoes may have provided sparks and chemistry for first life
3. MU brain imaging center provides research for autism, schizophrenia and Parkinsons disease
4. Brain structure provides key to unraveling function of bizarre dinosaur crests
5. Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate
6. Study provides insight on a common heart rhythm disorder
7. Field Museum provides gold standard for mammal survey
8. Paleozoic sediment curve provides new tool for tracking sea-floor sediment movements
9. Anabolic steroids provide a competitive edge in power lifting years after doping has ended
10. Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution
11. 1-hit event provides new opportunity for colon cancer prevention, say Fox Chase researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology: